Hikma Ventures announces strategic investment in Rem3dy Health
London, UK, 11 November 2026 – Hikma Pharmaceuticals PLC ("Hikma"), the multinational pharmaceutical company, today announced that its corporate venture capital arm Hikma Ventures, has made a new strategic investment in Rem3dy Health, a UK-based health technology company pioneering personalised nutrition through its proprietary 3D-printing platform. The transaction reflects Hikma's strategy of going beyond capital, using its commercial platform, regional expertise and market reach to turn promising healthcare innovation into scalable, commercially successful businesses.
Alongside the investment, Hikma and Rem3dy Health have recently entered an exclusive commercial agreement to bring the award-winning Nourished® brand to consumers across the Middle East and North Africa (MENA).
Founded by entrepreneur Melissa Snover, Rem3dy Health has developed and patented a breakthrough manufacturing technology capable of combining up to seven precisely dosed active ingredients into a single, personalized gummy "stack" tailored to individual consumer needs. With a portfolio protected by 29 patents, Rem3dy Health's technology enables the production of personalised nutritional supplements using natural ingredients and advanced data-driven personalisation algorithms. Through its flagship Nourished® brand, the company is redefining the future of wellness by delivering highly customised nutritional solutions at scale.
This strategic partnership with Rem3dy Health will support the company's expansion in MENA, initially focusing on key regional markets including Saudi Arabia and the United Arab Emirates, while leveraging Hikma's strong regional presence, extensive commercial capabilities, and local healthcare expertise.
Melissa Snover, Founder and CEO of Rem3dy Health said, “We are honoured to welcome Hikma Ventures as an investor in Rem3dy Health, marking an exciting new chapter in our growth journey. Hikma’s global reach, world-class healthcare expertise and extensive infrastructure make them an exceptional strategic partner, and their investment is a valued endorsement of our technology, its potential and our shared vision for the future. We look forward to building on the strong foundations of our existing commercial partnership and bringing together our complementary strengths to unlock new opportunities and accelerate innovation to improve lives through personalised health.”
"At Hikma, we are constantly looking for innovative companies that are shaping the future of healthcare. Rem3dy Health combines differentiated technology, strong consumer engagement, and a compelling vision for personalised wellness. This investment reflects Hikma Ventures' strategy of backing high-growth healthcare businesses that not only have significant commercial potential but can also create strategic value across Hikma's businesses and markets," said Lana Ghanem, Vice President Corporate Development at Hikma Pharmaceuticals and Managing Director of Hikma Ventures.
Together, the investment and commercial partnership demonstrate Hikma's increasingly integrated approach to innovation, combining strategic venture investing with commercial execution to accelerate the adoption of breakthrough healthcare solutions across the MENA region.
The transaction marks Hikma Ventures' first investment in the health and wellness innovation sector, expanding its portfolio of strategic healthcare investments. Since its inception, Hikma Ventures has invested in more than twenty healthcare companies across areas including digital health, predictive analytics, connected devices, smart inhalers, telemedicine, diagnostics, and AI-enabled healthcare solutions.